Turn dense science, development progress and funding logic into a presentation investors can scan, question and discuss. Rudrriv structures and designs biotech decks around the evidence you supply—without rewriting scientific uncertainty as certainty.
This is a presentation design and communication service. Scientific, clinical, regulatory, legal and investment claims remain subject to your internal review and approval.
A ten-slide design refresh and a multi-program investor deck with dense scientific figures are different projects. Rudrriv confirms a scope-based quote after reviewing the current deck, source material, audience, requested outputs and deadline.
For teams with approved content that mainly needs stronger hierarchy, visual consistency and cleaner charts.
Planning range: often about 5–7 working days for a focused, content-ready deck.
For fundraising or investor-update decks that need the story reorganized around evidence, pipeline, milestones and the financing objective.
Planning range: commonly about 7–10 working days when source material is complete and review is consolidated.
For decks with multiple assets, dense scientific figures, substantial appendices, partnering logic or audience-specific variants.
Planning range: often about 10–15 working days; larger scopes are scheduled after review.
Share the current deck or describe the scope. We will identify whether you need a focused redesign, narrative restructuring or a more complex data-heavy presentation build.
Generic pitch-deck design often treats the presentation as a sequence of business slides. Biotechnology investors may also need to understand mechanism or platform logic, evidence quality, development stage, program prioritisation, regulatory dependencies, manufacturing or partnering assumptions and the milestones the financing is intended to unlock.
The slide design needs enough scientific detail to remain credible while still making the core thesis and decision point visible.
A discovery platform, preclinical asset, clinical-stage company and multi-asset portfolio require different emphasis, evidence density and milestone framing.
Charts, tables and scientific figures need titles, units, cohort or study context, readable legends and source notes that preserve the meaning of supplied evidence.
Where the client has approved the underlying assumptions, the deck can connect proposed capital use to development activities and expected decision milestones.
Not every presentation needs every section below. The sequence depends on company stage, audience and the financing or partnering objective. The goal is to remove avoidable jumps between science, evidence, development plan and the commercial ask.
What is different, why it matters and what the company is building.
Keep the opening proposition precise enough to survive deeper technical scrutiny.Frame the unmet need, target, mechanism or platform logic using approved source material.
Avoid turning scientific uncertainty into marketing certainty.Show preclinical, translational or clinical evidence with labels that make the conclusion traceable.
Use figure hierarchy before adding more callouts.Make lead assets, indications, stages, ownership and program relationships easy to compare.
Separate current status from future intent.Organise milestones, studies, regulatory steps and major dependencies around the approved plan.
State assumptions where timing is conditional.Present market context and competitive positioning using client-supplied or approved evidence.
Keep comparators and sources explicit where used.Connect use of proceeds to the activities and milestones the raise is intended to support.
The deck should not imply guaranteed timing or outcomes.Close with the leadership relevance, transaction objective and clear investor discussion point.
Appendix depth can support technical diligence without slowing the core story.Data-heavy biotech slides often become difficult to scan because titles, legends, units, footnotes and interpretation compete for the same space. The design job is to establish a hierarchy that lets the audience locate the claim, inspect the evidence and find the supporting context.
A biotechnology investor deck becomes harder to follow when pipeline status is shown in one place, milestone timing in another and use of proceeds somewhere else. Where the company has approved the underlying information, these elements can be designed as one connected decision story.
You do not need every item below before enquiring. The scope review identifies what exists, what is missing and what must be approved internally before design work can proceed.
PPTX, Keynote export, PDF, storyboard or even a structured slide outline showing the intended investor narrative.
Editable charts where available, source tables, figure notes, units, legends and the approved interpretation you want the slide to support.
Program names, indications, current stages, next milestones, expected timing language and any partnership or ownership context approved for disclosure.
Logo, colours, fonts, presentation master, illustration rules and any investor-relations design conventions already used by the company.
Forward-looking statement language, legal or regulatory notes and any mandatory wording should be supplied exactly as approved.
Fundraising stage, investor type, conference, partner meeting, board update or other context that changes how much scientific and commercial depth belongs in the core deck.
The exact deliverable list is confirmed in the project scope. The examples below show the practical difference between the work performed and the files or assets the customer receives.
Reorder or restructure supplied content so the investor story moves logically from thesis to evidence, development plan and financing objective.
Improve supplied charts, tables, pipeline views and milestone graphics while retaining the underlying information and approved interpretation.
Apply a consistent slide system for typography, callouts, evidence notes, section transitions, appendices and repeated program content.
Handoff can include editable PPTX plus a PDF export, with agreed master-slide or reusable visual components where included in scope.
Design or clarity questions can be surfaced during review when content appears inconsistent, overloaded or difficult to interpret visually.
Footnote and source-reference patterns can be standardised so evidence provenance remains readable across the deck.
Clear boundaries protect both presentation quality and factual responsibility. A deck can look polished without implying that Rudrriv has independently validated the science or investment case.
| Scope area | Standard presentation-design work | May require custom scope | Outside this service |
|---|---|---|---|
| Narrative | Reorganising supplied content for clearer investor flow. | Substantial rewriting, new story development or multiple audience variants. | Investment advice, securities advice or fundraising guarantees. |
| Scientific content | Formatting approved wording, evidence and context. | Extensive technical editing across many programs or appendices. | Independent scientific, medical or clinical validation. |
| Charts & figures | Redesign from supplied data, labels and approved interpretation. | Complex custom illustration, multi-panel figure reconstruction or new data analysis. | Changing source data to improve the investment case. |
| Regulatory / legal | Placing client-approved statements and disclaimers. | Complex disclosure-format requirements supplied by advisers. | Regulatory, legal, compliance or disclosure advice. |
| Financial content | Designing supplied financing and use-of-proceeds information. | Complex scenario visualisation from client-approved models. | Financial audit, valuation opinion or financial-model assurance. |
If a requirement falls outside presentation design, it can be identified during scope review so the correct client-side specialist or separate service can be involved.
Quality review focuses on what presentation design can responsibly control: visual logic, consistency, legibility, traceability and handoff readiness.
The workflow is designed to avoid premature styling before the audience, story and evidence hierarchy are understood.
Review current deck, source files, audience, outputs and deadline.
Confirm the investor question, core thesis and required slide sequence.
Set typography, grid, colour, chart and biotech visual patterns.
Build evidence, pipeline, milestone, market and supporting slides.
Apply consolidated feedback within the agreed project scope.
Deliver agreed editable file(s), PDF export and reusable components.
Best suited to content-ready decks with limited chart reconstruction.
Typical when storyline changes and multiple biotech-specific visuals are required.
Planning range for complex figures, appendices, variants or extensive review cycles.
These answers define the practical service boundaries, source requirements and delivery logic before an engagement is scoped.
It is the structuring and visual design of an investor-facing biotechnology deck so scientific evidence, development stage, pipeline, milestones, commercial context, funding logic and key risks can be understood quickly. The service focuses on presentation architecture and communication, not on validating scientific claims.
Yes. An existing PPTX, Keynote export, PDF or slide outline can be used as the starting point. The scope can range from design cleanup to deeper restructuring when the current narrative is difficult to follow.
Rudrriv can help reorganize and refine supplied wording when included in scope, but the client remains responsible for the scientific accuracy, clinical interpretation, regulatory statements and approved claims in the final presentation.
Yes, when source data and approved interpretations are supplied. Tables, plots, cohort summaries, endpoint callouts and footnotes can be reformatted for presentation clarity without changing the underlying evidence.
Yes. Pipeline design can show programs, indications, development stages, ownership or partnership status and key milestones using the information you approve for investor use.
Yes. Milestone and catalyst timelines can be designed around the development events, data readouts, regulatory interactions, financing uses or partnering steps supplied by your team.
No. The service is presentation design and communication support. It does not include securities advice, fundraising guarantees, investor introductions, valuation opinions or legal advice.
No. Regulatory, clinical, medical and legal accuracy must be reviewed by the appropriate client stakeholders or advisers. Rudrriv can improve how approved statements are organized and displayed.
Useful inputs include the current deck or outline, approved company and program descriptions, source charts and tables, pipeline data, milestone dates, brand assets, approved disclaimers, investor audience context and any required presentation format.
The agreed handoff can include an editable presentation file and a PDF export, together with any agreed master-slide or reusable visual components. Exact formats are confirmed before work begins.
Pricing is scope-based because biotechnology decks vary widely in slide count, narrative maturity, number of programs, chart complexity, source-file quality, review requirements, requested variants and turnaround.
A focused design refresh can often be planned in roughly 5–7 working days, while narrative restructuring or data-heavy multi-program decks may require around 7–15 working days. Final timing is confirmed after source files and review requirements are assessed.
Review and correction rounds are defined in the agreed scope. Consolidated feedback is used to refine the approved presentation direction; material new content or a substantially changed story may require a scope update.
Yes, this can be scoped when the presentation needs a concise core story plus supporting scientific, clinical, market or technical appendix slides.
Yes, variant decks can be scoped when a company needs different emphasis for venture investors, public-market investors, strategic partners, board discussions or conference meetings.
The initial enquiry should contain only enough information to define the requirement. Sensitive source files should be shared through the project workflow agreed after scope review rather than pasted into the public enquiry form.
Rudrriv reviews the presentation objective, current materials, scientific and visual complexity, required outputs and timing. Clarification may be requested before scope, pricing and delivery expectations are confirmed.
Email ID, Phone and Requirement Details are required. Name is optional.
